comparemela.com
  1. Home
  2. Live Updates
  3. Alpine Study Data - Breaking News

Latest Breaking News On - Alpine study data - Page 1 : comparemela.com

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, MD, PhD, presents data from the extended follow-up of the ALPINE study investigating zanubrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

San diegoUnited statesJenniferr brownExtended follow upZanubrutinib versus ibrutinibRefractory chronic lymphocytic leukemiaSmall lymphocytic lymphomaPartnership withAlpine studyChronic lymphocytic leukemiaBtk inhibitorCll treatmentAlpine trialAlpine study dataAlpine study resultsAlpine extended follow up

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.